The TRG supports researchers in developing a translational strategy of their ideas to de-risk projects and make them more attractive to translational funding and industry investment for NHS adoption.
Successful translation of an idea into a NHS-adopted therapy is reliant upon strategic planning and effective decision-making by a diverse group of individuals.
Translation of fundamental and clinical research findings requires the collaborative consideration of arguably the two biggest research concerns, namely risk and resources. Regardless of investigator altruistic drivers, clinical evaluation of the safety and efficacy of novel therapeutics has significant costs.
UCL has established the TRO to provide core support to its investigators in the strategic development of their ideas so that they identify and mitigate risks early on, accelerate product progression from ‘bench-to-bedside’ and maximise attractiveness for public fund, philanthropic and industry investment to ensure patient benefit.
Please contact us if you require our help.